Syngene forays into commercial manufacturing of new molecules

Dr Manoj Nerurkar is the COO of Syngene, a CRO and a subsidiary of Biocon. In his exclusive interview with BioSpectrum’s Raj Gunashekar, he talks about Syngene’s collaborations with Endo Pharmaceuticals, BMS and recently, with Baxter.


Dr Manoj Nerurkar, COO, Syngene

In 2013, the company achieved revenues close to $100 million. Going forward, it aspires to touch the $250 million mark by 2018, through strengthening its current discovery and development platforms. He also elaborately discusses on the company's future goals and collaborations between industry-academia.

Importantly, Dr Nerurkar charts out recent trends and major shifts seen among the Indian and global CROs. He also touches on the sensitive topic of clinical trials regulation in the country and how the company strategically plans to navigate through the turbulent times. Excerpts:

Are there any differences in your collaboration with Baxter and others like Endo Pharmaceuticals and BMS?
Dr Manoj Nerurkar: Syngene Baxter collaboration is strategic in nature similar to many of our other collaborations.

The Baxter Global Research Center (BGRC) that we inaugurated at Syngene earlier this year, is a part of Baxter's global strategy of building R&D collaborations with strategic partners. This collaboration will support Baxter in the Research and Development of medical products and devices to serve patients both in India and around the world.

A team of over 100 multidisciplinary Syngene scientists will be based at this dedicated Center of Excellence at Syngene in Biocon Park, Bangalore.


Previous 1 3 4 5 6 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email